Status:
COMPLETED
Human Liver Explants for HIF-1 Alpha Analysis/Comparison (HIF HCC)
Lead Sponsor:
Northwestern University
Collaborating Sponsors:
Northwestern University Feinberg School of Medicine
Conditions:
Liver Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the study is to compare levels of HIF-1 α (Hypoxia Inducing Factor 1-alpha) in patients who have been treated with various types of liver cancer treatments.
Detailed Description
In the currently ongoing retrospective aspect of the study, we will obtain pathologic tumor explant specimens from the tumor explant population from 8/1/1994 to 12/31/2005. We will prepare 5-10 slides...
Eligibility Criteria
Inclusion
- Adults, any gender ≥ to 18 years of age
- Previous, or current diagnosis of hepatocellular carcinoma (clinical or biopsy proven)
- Resection for hepatoma and/or transplant
- Patients with diagnosis of hepatocellular carcinoma from 8/1/94 thru 12/31/05 (retrospective) with biopsy, explant and/or liver transplantation here at Northwestern Memorial Hospital (NMH).
- Patients previously diagnosed or, recently diagnosed with liver cancer that were treated, currently are being treated our will potentially undergo treatment for the disease.
Exclusion
- Any subject outside of the above inclusion criteria
Key Trial Info
Start Date :
February 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2019
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT00866957
Start Date
February 1 2006
End Date
July 1 2019
Last Update
November 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern Memorial Hospital
Chicago, Illinois, United States, 60611